News & Publications – Sionna Therapeutics

Press Releases

June 8, 2023

Sionna Therapeutics Announces Presentation of Preclinical Data on NBD1 Stabilizers at 46th European Cystic Fibrosis Conference

January 5, 2023

Sionna Therapeutics Announces Advancement of Cystic Fibrosis Pipeline Programs and Presentation at J.P. Morgan 41st Annual Healthcare Conference

December 7, 2022

Sionna Therapeutics Announces IND Clearance and Phase 1 Initiation for SION-638 in Cystic Fibrosis

November 14, 2022

Sionna Therapeutics Announces Appointment of Vanya Sagar as Chief People Officer

November 3, 2022

Sionna Therapeutics Presents Preclinical Data Demonstrating Restoration of ΔF508-CFTR by Stabilizing NBD1 with SION-638 in Cystic Fibrosis

October 4, 2022

Sionna Therapeutics to Present at the North American Cystic Fibrosis Conference

August 1, 2022

Sionna Therapeutics Announces Formation of Scientific Advisory Board

June 6, 2022

Sionna Therapeutics Announces Appointment of Paul Clancy to Board of Directors

April 19, 2022

Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis

Our Presentations

ECFS | June 8, 2023

Poster – Novel CFTR Modulator Combinations Directly Address the ΔF508-CFTR NBD1 Stability Defect and Enable Full CFTR Correction

J.P. Morgan 41st Annual Healthcare Conference | January 9, 2023

Corporate presentation

Evercore ISI HealthCONx Conference | December 1, 2022

Webcast Link

Stifel Healthcare Conference | November 15, 2022

Webcast Link

NACFC | November 4, 2022

Oral Presentation – Novel Modulator Combinations Address the NBD1 Stability Defect Central to ΔF508-CFTR Dysfunction and Enable Full Correction

NACFC | November 3, 2022

Poster – Novel Modulator Combinations Address the NBD1 Stability Defect Central to ΔF508-CFTR Dysfunction and Enable Full Correction

Clinical Expert Videos

Guided by Clinical Experts in Cystic Fibrosis – Sionna Therapeutics sat down with members of its Clinical Advisory Board to hear their expert perspectives on the unmet needs in Cystic Fibrosis.